MXC products now for sale via leading UK e-tailer, Cult Beauty
Specialist medical cannabis company, MGC Pharmaceuticals (ASX:MXC) today announced that its range of MGC Derma and Derma Plus cosmetics products are now available on leading global online beauty store, Cult Beauty (Cultbeauty.com). The launch follows an earlier sales and distribution agreement between MXC’s European subsidiary, MGC Derma, and Cult Beauty.
Cult Beauty will offer 15 of MXC’s cannabidiol cosmetic products and its Derma plus skincare range for sale to its customers in the UK and around the world. Sales will be driven by a 6-month exclusive marketing campaign led by Cult Beauty and additional public relations and promotional activities, with feature articles already secured in leading fashion industry publications.
CultBeauty.com are expert curators and trend dictators. They distil the global beauty industry down to its brightest and best; from the latest scientific discoveries, to hundred-year-old remedies that have never been bettered.
Yet it remains a speculative stock and investors and investors should take a cautious approach to any investment decision made with regard to this stock.
The agreement with the world-renowned beauty products e-tailer provides MXC’s Derma division with a new platform to market its growing range of CBD-based skin care products to a new and more diverse global cosmetics market.
Roby Zomer, Co-founder and CEO, MGC Pharmaceuticals commented: “We’re excited our MGC Derma and Derma Plus products have been officially launched on the Cult Beauty online beauty site and are available to be purchased by its global customer base, where legally permitted.
“Cult Beauty is known for its careful selection, curation and promotion of the products available on its site. The launch places our products alongside some of the beauty industry’s leading cult products, providing exposure of our brand and product range to a whole new market, which is now hearing about the benefits of our CBD-based skincare range.”
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.